Business Description
Vera Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92337R1014
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.99 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.53 | |||||
Debt-to-EBITDA | -0.58 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 45 | |||||
3-Year EPS without NRI Growth Rate | 43.6 | |||||
3-Year FCF Growth Rate | 36.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.38 | |||||
9-Day RSI | 41.14 | |||||
14-Day RSI | 43.84 | |||||
6-1 Month Momentum % | 316.38 | |||||
12-1 Month Momentum % | 550.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.71 | |||||
Quick Ratio | 7.71 | |||||
Cash Ratio | 7.21 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.5 | |||||
Shareholder Yield % | -6.16 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -79.92 | |||||
ROA % | -54.09 | |||||
ROIC % | -1427.22 | |||||
ROC (Joel Greenblatt) % | -2250.04 | |||||
ROCE % | -60.3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 17.4 | |||||
Price-to-Tangible-Book | 17.4 | |||||
EV-to-EBIT | -21.69 | |||||
EV-to-Forward-EBIT | -20.09 | |||||
EV-to-EBITDA | -21.69 | |||||
EV-to-FCF | -22.44 | |||||
Price-to-Net-Current-Asset-Value | 18.03 | |||||
Price-to-Net-Cash | 20.43 | |||||
Earnings Yield (Greenblatt) % | -4.61 | |||||
FCF Yield % | -4.25 |